David Mack - Pmv Pharmaceuticals CEO, CoFounder
| PMVP Stock | USD 1.43 0.02 1.42% |
Insider
David Mack is CEO, CoFounder of Pmv Pharmaceuticals
| Age | 63 |
| Address | 1 Research Way, Princeton, NJ, United States, 08540 |
| Phone | 609 642 6670 |
| Web | https://www.pmvpharma.com |
David Mack Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Mack against Pmv Pharmaceuticals stock is an integral part of due diligence when investing in Pmv Pharmaceuticals. David Mack insider activity provides valuable insight into whether Pmv Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Pmv Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pmv Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Mack over a month ago Disposition of 17709 shares by David Mack of Pmv Pharmaceuticals at 0.53 subject to Rule 16b-3 | ||
David Mack over three months ago Disposition of 9000 shares by David Mack of Pmv Pharmaceuticals at 0.53 subject to Rule 16b-3 | ||
David Mack over six months ago Acquisition by David Mack of 85500 shares of Pmv Pharmaceuticals at 0.53 subject to Rule 16b-3 |
Pmv Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2027) % which means that it has lost $0.2027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2363) %, meaning that it created substantial loss on money invested by shareholders. Pmv Pharmaceuticals' management efficiency ratios could be used to measure how well Pmv Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to drop to -0.41. As of 02/26/2025, Non Current Liabilities Other is likely to grow to about 16.2 M, while Total Current Liabilities is likely to drop slightly above 9.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Patrick Amstutz | Molecular Partners AG | 50 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Yuichi MD | MediciNova | 75 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 53 | |
| Spyridon MD | Vigil Neuroscience | 51 | |
| Caroline Godfrey | PepGen | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Jochen Knolle | Pharvaris BV | 74 | |
| Niels Svenstrup | PepGen | 55 | |
| MD MBA | Opthea | N/A | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Michael Gait | PepGen | N/A | |
| Annie Lee | Opthea | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 66 | |
| Alexander Zurcher | Molecular Partners AG | 50 | |
| Anne Lesage | Pharvaris BV | 64 | |
| John CPA | MediciNova | N/A | |
| Kory CPA | Entrada Therapeutics | 45 | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.2 |
Pmv Pharmaceuticals Leadership Team
Elected by the shareholders, the Pmv Pharmaceuticals' board of directors comprises two types of representatives: Pmv Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pmv. The board's role is to monitor Pmv Pharmaceuticals' management team and ensure that shareholders' interests are well served. Pmv Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pmv Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leila MD, Chief Officer | ||
| Winston MBA, COO CFO | ||
| Marc MD, Senior Affairs | ||
| Tim Smith, Senior Relations | ||
| Robert Ticktin, Head Counsel | ||
| Deepika PharmD, Chief Officer | ||
| Laura Leon, VP Operations | ||
| Crystal Zuckerman, Vice Resources | ||
| Arnold Levine, Independent CoFounder | ||
| Michael Carulli, Chief Officer | ||
| Binh Vu, Senior CMC | ||
| Thomas Shenk, CoFounder Board | ||
| David Mack, CEO, CoFounder | ||
| Robert JD, Head Counsel |
Pmv Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pmv Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | (95.32 M) | ||||
| Shares Outstanding | 51.75 M | ||||
| Shares Owned By Insiders | 2.30 % | ||||
| Shares Owned By Institutions | 81.65 % | ||||
| Number Of Shares Shorted | 859.15 K | ||||
| Price To Book | 0.38 X | ||||
| EBITDA | (78.88 M) | ||||
| Net Income | (68.96 M) |
Additional Tools for Pmv Stock Analysis
When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.